*Cryptococcus neoformans* is an opportunistic fungal pathogen that causes severe infection of the central nervous system. Inhalation of this microbe, as either a spore or desiccated yeast cell ([@B41]), causes a pulmonary infection that in immunocompetent individuals is minimally symptomatic, although it may remain latent for extended periods of time ([@B62], [@B8]). In severely immunocompromised individuals, however, *C. neoformans* can disseminate from the lungs and cross the blood-brain barrier ([@B103]), causing an often-lethal meningoencephalitis. Close to 220,000 cases of cryptococcal meningitis are reported annually. These result in over 180,000 deaths worldwide, including 15% of all AIDS-related deaths ([@B89]). Mortality rates range from 10 to 75% ([@B27], [@B52]), even with carefully developed treatment regimens ([@B85]), due to challenges that include drug toxicity, efficacy, cost, and availability. Increasing drug resistance has also been reported ([@B109], [@B17], [@B110]). Clearly, improved therapies are needed to combat this infection.

The outer layers of *C. neoformans* have unique features that may offer directions for drug discovery. These consist of three concentric structures: the capsule, cell wall, and plasma membrane ([Fig. 1A](#f1){ref-type="fig"}, left). The outermost layer, the polysaccharide capsule, is the hallmark of this organism and is required for virulence. This highly dynamic structure modulates fungal interactions with immune cells. Capsule components are also shed into the environment, where they further influence the host response and may be exploited for diagnosis and monitoring of cryptococcal infection ([@B2]). Both capsule thickness and shedding are tightly regulated in response to environmental conditions ([@B61], [@B71]).

![(A) Electron micrographs of *Cryptococcus neoformans.* Left, quick-freeze deep-etch image of cells grown in capsule-inducing conditions (as in [@B44]); right, transmission image of cells grown in rich medium (YPD), which yields only thin capsules. C: capsule; W: cell wall; PM: plasma membrane; M: mitochondrion; O: outer cell wall layer; I: inner cell wall layer. (B) Fluorescent micrograph highlighting the cell wall and capsule. Cryptococcal cells were induced to form capsule and stained with florescein (green) to label the cell wall and monoclonal antibody 2H1 (blue, generously provided by Arturo Casadevall) to label the capsule, as in [@B86]). (C) Quick-freeze deep-etch image highlighting the two layers of the cell wall.](0074-0276-mioc-113-7-e180040-gf01){#f1}

Below the capsule, and anchoring it, lies the fungal cell wall. This complex structure surrounds the plasma membrane and helps the cell withstand environmental challenges such as osmotic and mechanical stress. It is composed of glucans, chitin, chitosan, and glycosylated proteins ([@B42]). Melanin pigment associated with the cell wall further helps *C. neoformans* resist environmental stress and antifungal drug toxicity.

The innermost of the three layers we will consider is the plasma membrane. Unique features of fungal membranes are already the targets of several important classes of antifungal drugs, the polyenes and azoles. The plasma membrane is also the site of multiple proteins implicated in fungal virulence and has been implicated in the production of extracellular vesicles with potential roles in virulence ([@B99], [@B12], [@B54], [@B95]).

The unique features of the cryptococcal capsule, cell wall, and plasma membrane demonstrate fascinating fundamental biology that may potentially be exploited for therapy. Below we review current knowledge of these structures and their synthesis, and highlight some open questions in the field. We do not address the regulation of these structures in this short article, but refer interested readers to recent reviews that address this important topic ([@B31], [@B40], [@B83], [@B5], [@B62], [@B113], [@B2], [@B95], [@B42]).

*The capsule* - The polysaccharide capsule is a major cryptococcal virulence factor, which impedes the host immune response and is required for fungal survival within the host. This structure is composed of two polymers, glucuronoxylomannan (GXM) and glucuronoxylomannogalactan (GXMGal), along with trace mannoproteins ([@B20], [@B31]). GXM, which typically has a molecular weight in the millions, consists of an a-1,3-linked mannose backbone substituted with glucuronic acid and xylose ([@B18], [@B20], [@B45]). GXMGal, roughly an order of magnitude smaller, is a galactan with galactomannan side chains bearing a variable number of xylose residues; the galactose backbone also bears galactofuranose (all sugars are pyranose where not specified) ([@B46], [@B87]). Mannose residues of both polymers may also be O-acetylated ([@B37], [@B87]). Based on analysis of shed capsule, GXM constitutes \~90% of the capsule mass and GXMGal the remainder ([@B19]), although this may differ for surface-associated capsule.

The reactions that incorporate individual monosaccharides into complex polysaccharides like those of the capsule or cell wall use activated sugar molecules, usually in the form of nucleotide sugars, as donors. These compounds are mainly synthesized in the cytosol, although most glycan biosynthesis, including the formation of capsule polysaccharides ([@B129]), occurs in the lumen of the secretory pathway. For this to occur, the precursors must be moved into the synthetic compartment by specific nucleotide sugar transporters (NSTs) ([@B14], [@B43]). *C. neoformans* transporters have been identified for all of the predicted capsule precursors: GDP-mannose ([@B24], [@B122]), UDP-galactose ([@B24], [@B77], [@B122], [@B66]), UDP-galactofuranose ([@B67]), UDP-glucuronic acid ([@B68]), and UDP-xylose ([@B67]).

Once nucleotide sugars are transported into the lumen of secretory organelles, they serve as substrates for specific glycosyltransferases, which mediate the synthetic reactions that form capsule polysaccharides. The complex structures of GXM and GXMGal suggest the involvement of multiple such enzymes. However, only a single glycosyltransferase, Cxt1, has been directly implicated in capsule synthesis. This β-1,2-xylosyltransferase is required to produce fully xylosylated GXM and GXMGal ([@B59], [@B58]). Two other cryptococcal glycosyltransferases have been biochemically characterized ([@B111], [@B94], [@B92]), but only one of them has specificity appropriate for a role in capsule production, and deletion of the corresponding gene does not alter capsule composition ([@B111]). It remains to be determined whether this reflects the presence of compensating activities or indicates that this enzyme does not participate in capsule synthesis. The many other activities required for capsule synthesis ([@B11], [@B60], [@B31]) are likely encoded by some of the \~70 putative glycosyltransferase genes observed in the *C. neoformans* genome ([@B16], [@B70]); future work will be required to identify them.

Most glycan synthetic machinery is localized to the Golgi, where elaboration of core glycans on lipids and proteins occurs and capsule is synthesized ([@B129]); Cxt1 also resides in this compartment (Klutts et al., unpublished observations). From here, the classical secretory pathway transports capsule material to the cell surface ([@B129]). There are several models for the subsequent incorporation of newly synthesized polysaccharides into the existing capsule, which propose that this material is incorporated either at its inner face, near the cell wall ([@B86], [@B22]), or at the outer edge of the structure ([@B130]).

Although capsule polysaccharides are generally described as linear polymers, they may also contain branches, as suggested by their viscosity and shape factor ([@B23]). Increased branching has been reported to confer increased resistance to oxidative stress, inhibit nitric oxide production by macrophages, and enhance fungal survival in serum ([@B23]). Interestingly, *Cryptococcus liquefaciens,* which has a capsule that is chemically identical to that of *C. neoformans* although with no evidence of branching, is not as adept at resisting predation by amoeba, a potential environmental host of Cryptococci ([@B4]). However, this difference in intracellular survival does not hold in mammalian macrophages, suggesting that the biological activity of capsular polysaccharide may be context-dependent ([@B3]) or other factors may be involved. The details of branch formation and its role in host-pathogen interactions are still unclear, but promise to be exciting areas of study.

Mannoproteins comprise a small fraction of the capsule mass ([@B19]). These polypeptides appear mainly in the inner region of the capsule, close to the cell wall ([@B53]); they may represent an integral part of the capsule or perhaps secreted proteins that are in transit through it. These predominantly cell wall proteins are discussed further below.

*The cell wall* - Moving inward from the capsule, the next protective barrier that surrounds *C. neoformans* is the cell wall ([Fig. 1B](#f1){ref-type="fig"}). This structure is essential for cell viability, because it protects the fungus from osmotic and other environmental stresses; it also serves as a scaffold for the capsule. The cell wall is composed of a- and β-linked glucans (glucose polymers), chitin (a polymer of β-1,4-N-acetyl-glucosamine), chitosan (deacetylated chitin), glycoproteins, and, in the presence of appropriate precursors, the pigment melanin ([@B1]). Because the wall contains multiple components that are not shared with mammalian hosts, it has been the focus of much research for the development of antifungal compounds.

The cryptococcal cell wall is arranged in two layers. In quick-freeze deep-etch electron micrographs the inner layer appears more striated and the outer one more particulate ([Fig. 1C](#f1){ref-type="fig"}); they also differ in electron density on thin section electron micrographs ([Fig. 1A](#f1){ref-type="fig"}, right). The inner layer is composed of β-glucans and chitin; mannoproteins and melanin are also most abundant in this layer although they occur throughout the cell wall ([@B118], [@B119]). The outer layer mainly contains a- and β-glucans ([@B91]).

Each of the wall components has a specific role in maintaining cell wall structure and function. β-1,3-glucan underlies the cell wall framework. It occurs as long polymers ([@B51]), with short β-1,6-glucan branches that crosslink the polymers to each other, as well as to chitin and glycoproteins ([@B93], [@B40], [@B42]). Chitin and chitosan contribute to maintaining the integrity and flexibility of the wall structure ([@B9]), while chitin and chitooligomers have been implicated in capsule architecture ([@B9], [@B98], [@B35]). a-1,3- glucans are required for tethering the polysaccharide capsule to the cell ([@B90], [@B91]).

Unlike capsule components, cell wall polysaccharides are made at the plasma membrane and extruded through it. Once outside the cell, they associate with each other and with cell wall proteins that have exited via the secretory pathway. Some of these interactions are directed by branching or cross-linking enzymes, which together establish the complex wall structure ([@B40], [@B36], [@B42]).

β-1,3-glucan is synthesized at the plasma membrane from UDP-glucose by Fks1. The antifungal drug caspofungin ([@B57]) targets Fks1 in other yeasts, but notably is not effective against *C. neoformans*, even though it inhibits the cryptococcal enzyme *in vitro* ([@B72]). The synthases Skn1 and Kre6 participate in formation of β-1,6-glucan, although their specific biochemical roles are not known; deletion of the corresponding genes also perturbs capsular architecture, likely due to disorganization of the underlying cell wall ([@B39]). Finally, a membrane-associated alpha glucan synthase \[Ags1; ([@B90])\] forms a-1-3-glucan.

Chitin is made at the plasma membrane by a family of chitin synthases. Although no individual family member is essential for *C. neoformans* viability, the deletion of genes encoding chitin synthase 3 (Chs3) and a chitin synthase regulator (Csr2) drastically impairs cell wall integrity ([@B9]). Unlike in other fungi, most of the chitin in *C. neoformans* is deacetylated to form chitosan, a polymer that confers extra flexibility on the cell wall. Cells from strains lacking all three chitin deacetylases (Cda1, Cda2, and Cda3) have no cell wall chitosan and exhibit defects in cell integrity ([@B6]). Chitosan is also essential for virulence ([@B7]), a feature that has been successfully exploited in using a chitosan-deficient strain of *C. neoformans* to induce robust protective immunity in a murine model of infection ([@B116]).

Another component of the cell wall that has been implicated in virulence is melanin, a negatively-charged polymeric and hydrophobic pigment made from phenolic or indolic precursors ([@B81]). This material is associated with the cryptococcal cell wall in a chitin-dependent manner ([@B6], [@B15]). Melanization enhances cryptococcal survival within natural predators, such as amoebae ([@B114]) or nematodes ([@B79]). Disruption of its synthesis during infection reduces cryptococcal dissemination ([@B82]) and virulence ([@B101]), possibly due to melanin-mediated inhibition of phagocytosis and modulation of host cell cytokine responses ([@B48], [@B76]). Melanization also increases resistance to antifungal compounds such as amphotericin B and caspofungin ([@B120], [@B74]), and to environmental stresses, including host oxidative and nitrosative responses ([@B121]).

Many proteins are present in the cell wall, most of them heavily modified with N- and O-linked glycans ([@B60], [@B65], [@B31], [@B92]). The majority of these originate as plasma membrane localized glycosylphosphatidylinositol (GPI)-linked polypeptides, which are transferred, along with part of their anchor glycan, to covalent linkage with cell wall β-1,6-glycans ([@B84], [@B78]). Computational analysis predicts over 50 GPI-linked proteins encoded by the cryptococcal genome ([@B28], [@B69], [@B65]); some of these have been confirmed in studies of the *C. neoformans* secreted proteome ([@B32]). Other proteins associate with the cell wall via non-covalent interactions, linkage to β-1,3-glucan ([@B128], [@B56], [@B42]), or disulfide bonds to polypeptides that are themselves covalently bound to structural glycans ([@B29], [@B50]); these processes are less well studied.

Multiple cell wall proteins have key functions in cryp-tococcal biology. Some have been implicated in the dynamic responses of the wall to environmental conditions, such as the GPI-linked β-glucanase Gas1 that acts in β-1,3-glucan remodeling ([@B65], [@B32]). Another important GPI-linked protein is phospholipase B1 (Plb1), which has been implicated in *C. neoformans* virulence ([@B104], [@B75]). Cell wall mannoproteins, small amounts of which can be found in the capsule (see above), are often 80-90% mannose by mass ([@B73]). They are highly immunogenic ([@B65], [@B126]) due to their activation of the mannose receptor on dendritic cells and consequent activation of T-cells, which leads to a protective immune response against *C. neoformans* ([@B112], [@B25], [@B26]). These proteins are being explored as an adjuvant component of a vaccine for cryptococcosis ([@B21], [@B63]).

Several cryptococcal mannoproteins have been studied in depth. The first one described, MP98, was shown to be involved in T-cell activation ([@B64]) and turns out to be the same protein as the chitin deacetylase Cda2 discussed above ([@B38]). This protein, despite originating as a GPI-anchored membrane protein, associates with the cell wall in a manner that is independent of its GPI structure and β-1,6-glucans; the enzymatic activity is associated with the membrane form ([@B38]). Other mannoproteins that have been studied include MP88, involved in T-cell activation ([@B47]), and others (MP84 and MP115) that have homology to chitin deacetylase and carboxylesterase proteins ([@B10]). MP84 has been reported to mediate adhesion of *C. neoformans* yeasts to lung epithelial cells, suggesting a role early in infection ([@B115]). Finally, the mannoprotein Cig1 participates in iron uptake and contributes to virulence in a mouse model ([@B55], [@B13]). Future studies of these and other cell wall proteins will further illuminate the synthesis and function of this complex structure, and may also advance efforts to develop vaccines or therapies.

*Plasma membrane* - Beneath the polysaccharide capsule and cell wall is the plasma membrane ([Fig. 1](#f1){ref-type="fig"}), which serves as a barrier to the passage of hydrophilic molecules ([@B117]). Fungal membranes are composed of sterols, glycerophospholipids, and sphingolipids ([@B33], [@B106]), although these differ in many respects from their mammalian counterparts. The plasma membrane also contains proteins, which maintain their association with the membrane via transmembrane domains, GPI anchors, or various lipid modifications ([@B102]). Membrane structure and composition are dynamic, and vary with the fungal species analyzed and the environmental conditions ([@B107], [@B127]).

Fungal membranes differ from those of mammals in containing ergosterol in place of cholesterol. This feature has been exploited by two major classes of antifungal drugs, Amphotericin B, which binds ergosterol, and the azoles, which inhibit its synthesis. *C. neoformans* also produces glycosylated ergosterols, termed sterylglycosides (SGs) ([@B125], [@B95]). Although the enzyme(s) responsible for SG synthesis has not been identified ([@B123]), a glucosidase involved in SG degradation (termed EGCrP2 or Sgl1) is known. Deletion of the corresponding gene yields growth arrest, abnormal budding, and abnormal vacuole morphology ([@B124]); it also eliminates virulence in a murine model ([@B96]). Interestingly, inoculation with this mutant protected mice against subsequent lethal doses of *C. neoformans* H99 and *Cryptococcus gattii* R265 ([@B96]).

Yeast glycerophospholipids resemble those of higher eukaryotes, although their fatty acid composition may vary, while glycosphingolipids are more distinct. One of the latter that has been studied in detail in *C. neoformans* is glucosylceramide (GlcCer) ([@B80]), which influences cryptococcal pathogenicity and is required for normal growth, resistance to alkaline conditions, spore production, and germination ([@B30]). GlcCer is formed by the enzyme glucosyl-ceramide synthase 1, which transfers glucose from the nucleotide sugar UDP-glucose to a ceramide backbone ([@B97], [@B95]); disruption of the corresponding gene abrogates growth and virulence ([@B97]). Notably, fungal GlcCer differs from that of other eukaryotes by the presence of a methyl group in the sphingoid base ([@B100]). Eliminating this methylation alters membrane integrity and reduces virulence ([@B108], [@B88]). Little is known about GlcCer catabolism, but a cryptococcal glucosylceramidase (EGCrP1) may act in GlcCer quality control ([@B49]).

Within the plasma membrane of eukaryotes, distinct microdomains are enriched in ergosterol, GlcCer, other sphingolipids, and GPI-proteins. Such 'lipid rafts' are also found in *C. neoformans*, although they contain more saturated fatty acids (e.g. palmitic and stearic acid), fewer unsaturated fatty acids (e.g. oleic and linoleic acid), and none of the very long chain fatty acids (\> 20 carbons) found in lipid rafts from mammalian cells and *S. cerevisiae* ([@B105]). Several virulence factors cluster in these domains, including the phospholipase Plb1 ([@B75]), the antioxidant Cu/ Zn superoxide dismutase ([@B105]), and the plasma membrane ATPase (Pma1) ([@B34]).

*Final thoughts* - The AIDS epidemic allowed the explosive emergence of opportunistic pathogens such as *C. neoformans*. The death toll caused by this fungus continues to be an enormous burden, especially in regions with limited health care resources. This impact, coupled with the challenges of drug cost, availability, toxic side effects, lengthy treatment regimens, and resistance, creates an urgent need for improved therapies.

*C. neoformans* is protected by concentric surface structures, each of which influences multiple aspects of pathogenesis. Unique features of these structures may offer targets for new antifungal agents, but many of them remain poorly defined. For capsule, we still do not know how GXM and GXMGal are arranged and associate with the cell, or most of the glycosyltransferases required for their synthesis. The mechanisms of capsule branching, shedding, and degradation also remain unexplored. Fungal cell wall synthesis is fairly well understood and has been successfully exploited for antifungal therapy by glucan synthase inhibitors, but this class of drugs is not effective against cryptococcal infection. Continued exploration of wall synthesis and regulation, and of cell wall proteins or strains defective in cell wall components that may act as vaccines, may help compensate for this gap in efficacy. Finally, the plasma membrane is the site of unique glycolipids whose synthesis and catabolism is yet to be fully elucidated; these and novel membrane proteins may offer targets for drug development or potential for diagnostics. Addressing these many fascinating questions, as we peel away the layers of this fascinating yeast, should lead to advances in fundamental biology and point the way to new ways to combat a formidable pathogen.
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